Abstract:E3 ubiquitin ligases are a large family of proteins that can be classified into three major structurally distinct types: N-end rule E3s, E3s containing the HECT (Homology to E6AP C-Terminus) domain, and E3s with the RING (Really Interesting New Gene) finger, including its derivatives, the U- Box and the PHD (Plant Homeo-Domain). E3 ubiquitin ligases exist as single polypeptide or multimeric complexes. Together with ubiquitin activating enzyme E1 and ubiquitin conjugating enzyme E2, E3 ubiquitin ligases catalyze the ubiquitination of a variety of protein substrates for targeted degradation via the 26S proteasome. E3 ubiqutin ligases, therefore, play an essential role in regulation of many biological processes. Furthermore, E3s are enzymes that determine the specificity of protein substrates; they represent a class of “drugable” targets for pharmaceutical intervention. In this review, I will mainly focus on E3 ubiquitin ligases as potential cancer targets and discuss three of the most promising E3s, Mdm2/Hdm2, IAPs, and SCF, for their target rationales, target validation, and critical issues associated with them. These E3 ligases or their components are over-expressed in many human cancers and their inhibition leads to growth suppression or apoptosis. In addition, I will evaluate two current methodologies available for the high throughput screening for small molecular weight chemical inhibitors of the E3 ubiquitin ligases. Although targeting E3 ubiquitin ligases is still in its infancy, speedy approval of the general proteasome inhibitor, Velcade (bortezomib) by the FDA for the treatment of relapsed and refractory multiple myeloma suggests the promise of specific E3 inhibitors in anti-cancer therapy. Emerging technologies, such as siRNA, will provide a better validation of many E3s. It is anticipated that E3 ubiquitin ligases will represent an important new target platform for future mechanism-driven drug discovery.

E3 ubiquitin ligases and deubiquitinases in colorectal cancer: Emerging molecular insights and therapeutic opportunities

The Involvement of E3 Ubiquitin Ligases in the Development and Progression of Colorectal Cancer

E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities

E3 Ubiquitin Ligases in Cancer and Implications for Therapies

E3 ubiquitin ligases as cancer targets and biomarkers.

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Targeting E3 Ubiquitin Ligases for Cancer Therapy

Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy

Deubiquitinases in cancer

Emerging Role of DUBs in Tumor Metastasis and Apoptosis: Therapeutic Implication

Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion

Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges

Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials

The Role of E3 Ubiquitin Ligases and Deubiquitinases in Bladder Cancer Development and Immunotherapy

Navigating therapeutic prospects by modulating autophagy in colorectal cancer

Epigenetics of colorectal cancer: biomarker and therapeutic potential

E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential

E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression

Comprehensive analysis of the role of ubiquitin-specific peptidases in colorectal cancer: A systematic review

The role of epigenetic therapies in colorectal cancer